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Abstract
Recently, we have shown how pharmacokinetic–pharmacodynamic (PKPD)
modeling can be used to assess the probability of QT interval prolongation both
in dogs and humans. A correlation between species has been identified for a
drug-specific parameter, making it possible to prospectively evaluate nonclinical
signals. Here, we illustrate how nonclinical data on methadone can be used to
support the evaluation of dromotropic drug effects in humans. ECG and drug
concentration data from a safety pharmacology study in dogs were analyzed
using nonlinear mixed effects modeling. The slope of the PKPD model describ-
ing the probability of QT interval prolongation was extrapolated from dogs to
humans and subsequently combined with methadone pharmacokinetic data as
input for clinical trial simulations. Concentration versus time profiles were sim-
ulated for doses between 5 and 500 mg. Predicted peak concentrations in
humans were then used as reference value to assess the probability of an
increase in QT interval of ≥5 and ≥10 ms. Point estimates for the slope in dogs
suggested low probability of ≥10 ms prolongation in humans, whereas an effect
of approximately 5 ms increase is predicted when accounting for the 90% cred-
ible intervals of the drug-specific parameter in dogs. Interspecies differences in
drug disposition appear to explain the discrepancies between predicted and
observed QT prolonging effects in humans. Extrapolation of the effects of race-
mic compound may not be sufficient to describe the increase in QT interval
observed after administration of methadone to patients. Assessment of the con-
tribution of enantioselective metabolism and active metabolites is critical.
Abbreviations
CYPs, cytochrome P450s; FTIH, first time in human; GLP, Good Laboratory Prac-
tice; NMDA, N-methyl-D-aspartate; PKPD, pharmacokinetic–pharmacodynamic.
Introduction
Drug-related prolongation of the QT interval has been a
cause of attrition and concern during the screening and
selection of candidate molecules (Shah 2007). Despite the
availability of multiple screening methods, experimental
protocols continue to be applied from early discovery
without clear understanding whether drug effects in these
experiments predict clinically relevant QT prolongation
when administered to humans at therapeutic doses. As a
consequence, uncertainty about the liability for QT
prolongation has been managed by estimating the effect
size in the so-called thorough QT study (TQT), which
has been a regulatory requirement for all drugs in devel-
opment for more than a decade.
Whereas alternative approaches have been recently pro-
posed, which shift the focus of screening procedures
toward the evaluation of proarrhythmic rather than dro-
motropic properties of compounds during preclinical
development, such a liability may not be fully dismissed
without further characterization of the underlying con-
centration–effect relationship. In fact, this represents an
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important caveat of the methodology for the estimation
of QT interval prolongation which has been recom-
mended over the last decade (FDA, 2005). The use of the
so-called double-delta method has been shown to cause
high false-positive rates and most importantly to ignore
the underlying concentration–effect relationship, given
that statistical significance is assessed at the dose/treat-
ment level (France and Della Pasqua 2015). These limita-
tions have prompted scientists and regulators to endorse
and consider careful evaluation of pharmacokinetic–
pharmacodynamic (PKPD) relationships during the analy-
sis of TQT study data. However, the whole approach
presents considerable limitations, as it does not enable
conclusive decisions to be taken about the development
of a new compound before Phase IIb or III. This situation
has led to the recent proposal to include appropriate QT
assessments in an earlier stage of the clinical drug devel-
opment. More specifically to characterize drug-induced
effects on QT interval during first-time-in-humans stud-
ies, during which single and multiple ascending doses are
evaluated. PKPD modeling can then be used as a tool to
assess the extent of QT/QTc prolongation in a strictly
quantitative manner (Darpo et al. 2014). These data
should be complemented by results from a comprehensive
in vitro proarrhythmia assay (CiPA) (Cavero and Holz-
grefe 2015; Sager et al. 2014; Fermini et al. 2016).
It should be highlighted that the premise for the ongo-
ing review of the guidelines is that QT interval prolonga-
tion is not a specific surrogate marker for the risk of
torsades de pointes. In fact, electrophysiological studies
have provided insight into the mechanisms of drug-
related arrhythmogenicity. Such studies are presently pur-
sued within the CiPA initiative (Fermini et al. 2016). It
can be anticipated that novel biomarkers will be identified
which ultimately can be of value for use as surrogate
markers. Meanwhile in the absence of specific markers,
the emphasis remains on the assessment of QT/QTc inter-
val prolongation prior to the regulatory approval drugs.
In addition, the approach proposed by the CiPA initiative
needs to consider that differences may exist between
in vitro and in vivo effects, which are not evident without
an integrated analysis of the data. Therefore, in this inves-
tigation, we show how drug effects can be scaled from
dog studies to humans. Ultimately the findings in these
studies may prove of value in the prediction of the QT
response at therapeutic doses. It can be envisaged that the
tandem of CiPA and PKPD modeling may yield a strong
basis for the evaluation of proarrhythmic risk.
We have recently shown that the use of a model-based
approach allows for the translation and extrapolation of
preclinical findings, as exposure–response relationships
can be derived using a common model parameterization
(Chain and Dubois et al. 2013; Chain et al. 2013; Dubois
et al. 2014, 2016a,b). In addition, the evaluation of a
range of compounds showing varying degrees of hERG
inhibition has revealed a correlation between drug-specific
model parameter estimates in dogs and humans, namely,
the slope describing the linear relation between drug con-
centration and QT interval prolongation (Dubois et al.
2016a,b). Whereas we acknowledge that additional com-
pounds with different proarrhythmic mechanisms should
be integrated into the analysis to ensure higher precision
of the parameter estimates, results obtained so far are
robust enough to enable prospective evaluation of the
clinical effects of new compounds with detectable hERG
activity.
To illustrate the implementation of an improved
screening procedure for new compounds, we have ana-
lyzed in a blinded manner pharmacokinetic and electro-
cardiographic data obtained from dogs after oral
administration of methadone at dose levels typically used
during in vivo safety pharmacology studies. These data
were used in combination with simulated pharmacoki-
netic data from a hypothetical phase I dose escalation
study in healthy subjects. The main goal of this investiga-
tion was to demonstrate the advantages of integrating
preclinical information into clinical trial simulations to
evaluate the potential effects at therapeutically relevant
concentrations. Our analysis was also aimed at identifying
the role of interspecies differences in drug disposition for
the accurate extrapolation and prediction of proarrhyth-
mic effects in humans. Finally attention was given to
experimental design requirements, as to ensure suitable
data are derived for modeling and simulation. Methadone
was selected as a paradigm compound primarily because
pharmacokinetic data and the corresponding effects on
QT interval were available both in conscious dogs and in
humans. Furthermore the effects of methadone on QT
interval are well established. Most importantly,
methadone was not included in the dataset that was used
to identify the interspecies correlation (Dubois et al.
2016a,b).
Methadone was first synthesized in 1939 at the phar-
maceutical laboratories of I.G. Farbenconzern, a sub-
sidiary of Farbwerke Hoechst, in Germany. One of the
key objectives of the research team was to identify effec-
tive analgesic properties that would be nonaddictive. In
fact, early experiments showed that the drug was both an
analgesic and a spasmolytic. Only in 1947, results of both
animal and human studies were presented in which doses
of methadone between 200 and 800 mg given four times
daily were described in relation to tolerance, physical
dependence, and abstinence syndrome. The discovery of
methadone’s unique pharmacokinetic properties did not
occur until 14 years later (Payte 1991). Today, it is well
established that methadone is an opioid receptor agonist
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(Selley et al. 2001) and also variably acts as an N-methyl-
D-aspartate (NMDA) receptor antagonist and adrenergic
(alpha-2) agonist (Codd et al. 1995; Gorman et al. 1997).
Methadone is marketed as a racemic mixture and has
high oral bioavailability and a long terminal half-life (23–
35 h) compared with many other opioids (Dale et al.
2002, 2004). In dogs, however, the oral bioavailability is
low and terminal half-lives range from 1.75 to 4 h and 2
to 12 h following intravenous (IV) and subcutaneous
(SC) administration, respectively. Methadone’s volume of
distribution is large and of the same magnitude in both
humans and dogs (Kukanich 2005; Kukanich and Borum
2008). The metabolic pathways of methadone have not
been fully characterized in dogs, but data show that it is
mainly extracted by the liver (Garrett et al. 1985) with
clearance values corresponding to 89% of the hepatic
blood flow in dogs (Davies and Morris 1993). This
implies that oral bioavailability in this species is low. By
contrast, in humans, methadone is a low-clearance drug
and the oral bioavailability is high (Meresaar et al. 1981).
In addition, multiple cytochrome P450s (CYPs) have been
identified in the metabolism of methadone, including
CYP3A4, CYP2C8, CYP2D6, and CYP2B6 (Wang and De
Vane Lindsay 2003; Totah et al. 2008).
The suspicion regarding methadone-induced torsado-
genic effects dates back to 1973 when Stimmel et al.
reported prolongation of the QTc interval in narcotic
drug addicted patients. Numerous publications have since
then emerged describing the potential link between QTc
interval prolongation and methadone use. An overview of
published findings can be found elsewhere (Mujtaba et al.
2013). The first case series was reported by Krantz et al.
who found an association between high-dose methadone
use (average dose of 400 mg/day) and TdP. However, no
pharmacokinetic information was available and 12 of
these 43 patients had hypokalemia or used another QTc
prolonging medication. More recently, a dose-dependent
effect of methadone on the QTc interval has been
reported, involving patients on oral methadone treatment
across a dose range 10–1200 mg/day.
Given the history of its development and the current
role of methadone in the therapeutic management of pain
and addiction, our investigation highlights the importance
of evaluating concentration–effect relationships when
characterizing the safety profile of a new molecule. An
important feature of the proposed modeling approach is
that it enables analysis of the effects at different thresh-
olds; that is, 10 msec (which is the upper confidence
interval threshold) as required by ICH E-14 (FDA 2005),
but also 5 msec (which is the threshold of the average
prolongation). This is particularly interesting for drugs
with a borderline effect such as methadone or for those
which show high propensity for pharmacokinetic drug–
drug interactions. Using clinical trial simulations, we
show how such data can be used in combination with
quantitative pharmacology concepts not only to stop the
development of unsuitable candidate molecules but also
to understand liabilities and mitigate risks during clinical
development.
Material and Methods
Dog study
Conscious male beagle dogs (n = 4) were given single
subcutaneous doses of vehicle (0.9% (w/v) sodium chlo-
ride pH 4.5+/ 0.1 adjusted) and methadone (Batch
Number, 028K1166, 89.5% pure as methadone, assigned
retest date of 22 January 2011) at 0.2, 0.6, and 2 mg/kg.
Arterial blood pressure, heart rate, electrocardiographic
intervals, QA interval (index of cardiac contractility), and
body temperature were monitored for 24 h after dosing.
Electrocardiographic waveforms were evaluated for distur-
bances in waveform rhythm and morphology following
treatment with vehicle and methadone at all doses. Blood
samples were taken for measurement of blood concentra-
tions of methadone at 1, 2, 4, 8, and 24 h postdose. All
animals had at least a 26-week wash-out period between
dose levels and underwent a health check by a site veteri-
narian prior to the start of the study. On the first day of
treatment the dogs were approximately 1.8–3.9 years old,
and in the weight range 13.03–15.15 kg. Animals received
injection volumes of 0.5 mL/kg, administered subcuta-
neously; the site of injection was changed every week. The
dose volume was calculated on the day of dosing from
the individual body weight (recorded weekly). Food was
withheld for approximately 21 h prior to each treatment,
and on treatment days, food was offered 1 h after dosing.
Methadone hydrochloride (Batch no. 028K1166, 89.5%
pure as methadone) was supplied by Sigma and was
stored at the appropriate storage conditions at room tem-
perature, protected from light. Solutions at concentrations
of 0, 0.4, 1.2, and 4 mg/mL methadone in 0.9% (w/v)
aqueous sodium chloride, pH 4.5 adjusted, were prepared
shortly prior to dosing as no stability information was
available for methadone hydrochloride in this vehicle.
All experiments were approved by the ethical commit-
tees and performed under Good Laboratory Practice
(GLP) regulations. The animals were housed singly and
the environmental controls were set to maintain tempera-
ture at 19  2°C in the holding bay in which there was a
12-h light/12-h dark cycle. Dogs were fed Harlan Teklad
2021C Dog Maintenance diet except when treated and
provided with Datesand Grade 6 bedding. Filtered water
was available ad libitum. Summary study details are pro-
vided in Table 1. Details of the bioanalysis and
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subsequent modeling of the data can be found in the sup-
plemental material.
Prediction of QT prolongation in humans
In order to accurately simulate the putative drug-induced
QT-prolonging effects in a clinical trial in human sub-
jects, two different scenarios were considered: (1) A ran-
domized, placebo-controlled, crossover, dose-escalation
study, similar to a typical first-time-in-human (FTIH)
protocol with a small group of subjects (N = 27), in
which a range of doses are evaluated in an escalating
manner in conjunction with an active comparator; and
(2) a thorough QT study (TQT) in which a larger group
of subjects (N = 60) are administered no more than two
or three dose levels according to a parallel and a cross-
over design.
To evaluate such scenarios, pharmacokinetic data have
to be simulated for all subjects using a preliminary PK
model from single doses of the compound. These data
reflect typical single ascending dose pharmacokinetic pro-
tocols in phase I trials. As no detailed information about
drug metabolism in humans is available at this stage of
development, it was assumed that active metabolites (i.e.,
with potential proarrhythmic effects) are not formed. The
individual pharmacokinetic profile in humans was then
simulated 150 times for each of the scenarios highlighted
above. For a full overview of the different study designs
see Table 2.
To ensure realistic levels of variability in the simulation
of drug effects on QT interval, RR profiles had to be gen-
erated for each subject. This was performed using a large
pool of ECG data from healthy subjects (n = 776, 339
males and 437 females) with an average age of 31.1 (SD
9.4) years. The starting RR interval (RR0) used in the
simulations was based on the pooled data. This procedure
was aimed at mimicking variability and dispersion in real
subjects. Details of the RR simulation method can be
found in Bellanti et al. (2011). A frequent sampling
scheme was used to generate RR intervals (Table 3). The
selected sampling times are in line with safety monitoring
procedures in a typical Phase I protocol.
Using the predicted drug concentrations and RR inter-
vals for each subject, QT intervals were simulated based
on the PKPD model, taking into account the translational
factor of 11.6 (Dubois et al. 2016a,b) (see supplemental
material). The parameters describing the circadian
rhythm were fixed to the values estimated previously
(Dubois et al. 2016a,b), namely, 4.224 msec for the
amplitude and 9.9 h for the phase. On both parameters,
a 10% variability was allowed, including a residual error
of 5.3 msec.
Probability of QT interval prolongation
The model-predicted effects of methadone are described
in terms of the probability of QT prolongation above the
clinical threshold of 5 and 10 msec. The Bayesian analysis
was performed with a step function in WinBUGS 1.4
using the a posteriori slope estimates and an interindivid-
ual correction factor for gender differences (see Equations
1 and 2) at arbitrary concentration points between 5 and
1,00,000 nM. Data were summarized and presented in
nanomolar (nM). The concentration values were chosen
in such a way that data points cover the complete sig-
moid curve.
P 10ms (at C) ¼ step

0:00001FðgenderÞ  slope  5ms
C

(1)
P10ms (at C)¼ step

0:00001FðgenderÞ  slope  10ms
C

(2)
where 0.00001 is set as an arbitrary small number to avoid
computational errors associated with numerical difficulties
(i.e., division by zero), 5 or 10 ms represent the QT interval
prolongation threshold of interest, C is the drug
concentration, and slope is the QT increase per unit drug con-
centration. Probability curves were plotted for each scenario.
Results
Pharmacokinetic modeling in dogs
The time course of drug concentrations in dogs was ana-
lyzed in a blinded manner using nonlinear mixed effects
modeling. The pharmacokinetics could be described by a
Table 1. Experimental protocol design and sampling times in dogs
Number of
animals
4
Gender M
Weight [kg] 14 (13–15.5)
Dose [mg/kg] 0, 0.2, 0.6, 2.0
PK sampling
times [h]
0, 1, 2, 4, 8, 24
PD sampling
times
Every 30 sec, averages over 24 h
PK parameter Plasma concentration
Vital signs Heart rate, blood pressure,
Demographic
covariates
Weight, sex
ECG parameters MBP, SBP, DBP, PP, PR, QT, HR, RR, QRS, Temp
DBP, diastolic blood pressure; HR, heart rate; MBP, mean blood pres-
sure; SBP, systolic blood pressure; Temp, body temperature.
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one-compartment model with oral absorption and
interindividual variability on clearance and volume of dis-
tribution. The predicted profiles are depicted in Figure 1.
A summary of the pharmacokinetic model and final
parameter estimates is shown in Table S1 (see
supplemental results). As most of the pharmacokinetic
samples were taken at different time points relative to the
ECG recordings, individual predicted concentrations were
required to generate time-matched data for subsequent
evaluation of drug effects by PKPD modeling.
Table 2. Design characteristics of the FTIH and TQT studies used in the simulations of drug-induced QT effects in humans.
Study design
Scenario FTIH crossover TQT crossover
TQT crossover with
time-matched baseline
TQT parallel design with
time-matched baseline
Treatment
(dose levels)
5 dose levels, 3 consecutive
escalating doses,
placebo controlled, and
an active control
1 dose (top dose
from FTIH),
placebo controlled,
and an active control
1 dose (top dose from FTIH),
placebo controlled, and
an active control
1 dose (top dose from FTIH),
placebo controlled, and
an active control
Sample size N = 27 N = 60 N = 60 N = 60
Baseline QT Baseline QT sampled 3 h
before dosing
Baseline QT sampled
3 h before dosing
Time-matched baseline QT
sampled on the day
before dosing
Time-matched baseline
QT sampled on the day
before dosing
Randomization 3 cohorts:
Cohort 1: placebo, 40, 80,
and 120 mg methadone
Cohort 2: placebo, 120, 160
and 200 mg methadone
Cohort 3: placebo, 200, 250,
and 500 mg methadone
2 cohorts:
Cohort 1: first 500 mg
methadone, then placebo
and an active control
Cohort 2: first placebo, then
500 mg methadone and an
active control
2 cohorts:
Cohort 1: first 500 mg
methadone, then placebo
and an active control
Cohort 2: first placebo, then
500 mg methadone and
an active control
2 cohorts:
Cohort 1: placebo
Cohort 2: first placebo, then
500 mg methadone
Cohort 3: first placebo then
an active control
Threshold for
the probability
of QT interval
prolongation
5, 10 ms 10 ms 5, 10 ms 10 ms
FTIH, First-time-in-human; TQT, thorough QT.
Table 3. Population PKPD parameter estimates obtained from the simulation of methadone-induced QT-prolonging effects in FTIH and TQT stud-
ies.1
Parameter
FTIH
average
10 ms
FTIH
average
5 ms
FTIH
WCS
10 ms
FTIH
WCS
5 ms
TQT crossover
time-matched
BL average
10 ms
TQT crossover
time-matched
BL average
5 ms
TQT crossover
time-matched
BL WCS
10 ms
TQT crossover
time-matched
BLWCS
5 ms
Slopem (ms/nM) 6.13E-05 6.30E-05 6.61E-04 6.61E-04 2.62E-04 2.62E-04 6.70E-04 6.89E-04
Slopef (ms/nM) 6.37E-05 6.55E-05 6.86E-04 6.86E-04 2.72E-04 2.72E-04 6.96E-04 7.15E-04
Alpha 0.338 0.338 0.338 0.338 0.339 0.339 0.338 0.338
Amplitude (ms) 4.20 4.20 4.22 4.22 3.13 3.13 3.13 3.18
Phase (h) 9.93 9.93 9.92 9.92 10.38 10.38 10.37 10.35
QTc0m (ms) 387.3 387.3 387.3 387.3 387.4 387.4 387.4 387.4
QTc0f (ms) 402.3 402.3 402.3 402.3 402.3 402.3 402.3 402.3
Simulated data were analysed using the PKPD model developed previously by Chain et al (2011). Predicted drug concentrations in humans and RR
data were used in conjunction with extrapolated estimates of the slope parameter observed in dogs. The interspecies correlation for this drug-spe-
cific parameter is based on the assumption that QT prolongation is determined by hERG inhibition mechanisms. BL, baseline; FTIH, First-time-in-
human; TQT, thorough QT; WCS, worst case scenario.
1An overview of all PKPD parameter estimates including alternative scenarios and 95% credible intervals is available in table S1 (supplemental
results).
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Pharmacokinetic–pharmacodynamic
modeling of the dromotropic effect in dogs
The data analysis was performed using the recorded ECG
measurements and predicted drug concentrations at the
corresponding sampling time. Model parameters are sum-
marized in Table S2 (supplemental results). It is worth
mentioning that system-specific parameters, that is, base-
line QT (QT0), the QT-RR correction factor (a), the
amplitude (A), and phase (Ф) showed values within
the same range observed in previous experiments. On the
other hand, parameter estimates for a, A, and Ф were
characterized by relatively low precision. Such a low pre-
cision may be caused by a possible delay in the QT adap-
tation to changes in RR, as shown in Figure 2. Based on
the final slope estimates, the model predicted a small but
positive QT-prolonging effect in dogs. This corresponded
to a probability of 0 for a QT interval prolongation ≥
5 msec and ≥10 msec at Cmax.
Simulation scenarios and prediction of the
dromotropic effect in humans
Despite the limited experimental data available for the
estimation and extrapolation of the slope parameter from
dogs to humans, the different scenarios proposed here
attempt to account for the uncertainty or lack of preci-
sion in this drug-specific parameter. The slope parameter
in humans was therefore derived from the mean and
upper 95 credible interval of the estimates obtained in
dogs, namely, 0.000019 and 0.059 ms/lmol; these values
were obtained using the 11.6 translational factor, which
describes the differences in effect between the species for
(Dubois et al. 2016a,b). Based on these values, QT
Figure 1. Methadone pharmacokinetics in dogs and human subjects. Concentration versus time profiles are shown in dogs (left) and in humans
(right). Lines depict predicted profiles, whereas symbols indicate observed data. Experimental protocol in dogs included methadone doses of 0.2
(green), 0.6 (red), and 2 mg/kg (dark blue). Human data were simulated to mimic a cohort of 27 subjects with 7 arms, including doses of 5
(green), 10 (red), 25 (blue), 50 (pink), 100 (brown), 250 (purple), and 500 mg (orange), with IIV variability in drug disposition parameters. Note
that due to species differences in pharmacokinetics, methadone exposure after administration of a 500 mg dose yields plasma levels
approximately 10-fold higher than the concentrations observed in a typical safety pharmacology protocol in dogs.
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intervals were simulated using the predicted methadone
concentrations at the proposed dose levels in the context
of a Phase I dose escalation (FTIH) protocol and a TQT
study, as summarized in Figure S1 and in Table S1 (sup-
plemental results).
The results from the simulations are summarized in
Figures 3–4. It should be noted that consistent results
with acceptable variability were obtained for system-speci-
fic parameters in all the scenarios (Table 3). The proba-
bility curves show that a FTIH is less likely to pick up a
possible QT prolongation ≥10 ms in a limited number of
subjects, as compared to results observed in a dedicated
protocol, in which a fixed supratherapeutic dose level is
used across all subjects. On the other hand, the use of dif-
ferent thresholds for QT prolongation has revealed some
important features of the dromotropic effects of metha-
done. Clearly, a different pattern arises from estimates
based on a lower threshold for prolongation of 5 ms, as
compared to 10 ms. At the predicted peak concentrations,
the probability of QT interval prolongation ≥ 5 ms ran-
ged between 0 and 0.51 based on the mean and upper
boundary of the 95% credible interval for the slope
parameter, respectively. These findings suggest that at
therapeutic levels methadone is likely to prolong QT
interval, but absolute changes may range between 5 and
10 ms. An overview of these findings is summarized in
Table S3 (supplemental results).
Discussion
The lack of quantitative measures describing the QT-
prolonging effects in preclinical assays can lead to poten-
tially life-saving drugs being discarded prior to their
progression into clinical development, whereas other
compounds may reach clinical trials despite their proar-
rhythmic activity (Wallis 2010). In this investigation we
Figure 2. Predicted QT profiles after administration of different doses of methadone to dogs (left) and humans (right). In humans, drug-induced
effects are based on the extrapolation of the slope parameter observed in dogs. Observations are indicated by symbols and population predictions
by lines. Time is the time after dose in hours. In dogs ○ (gray) and _____ are predose values; M (red) and _ _ _ _ represent 0.2 mg/kg; + (blue) and
- - - - 0.6 mg/kg, } (light blue) and __ __ __ 2 mg/kg methadone. In humans, different colours are used to depict each dose level, namely 5
(green), 10 (red), 25 (blue), 50 (pink), 100 (brown), 250 (purple), and 500 mg (orange) methadone.
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have shown the implementation of a model-based
approach for prospective evaluation of the dromotropic
effects of new candidate molecules. Methadone was
selected as a paradigm compound, given the long-stand-
ing debate about the magnitude of its QT-prolonging
effects and absence of data regarding hERG inhibition at
the time of its development. Using extrapolated estimates
from the slope parameter in dogs, we have shown how
quantitative pharmacology methods can be used as a tool
for experimental protocol optimization and prediction of
drug effects at clinically relevant concentrations in
humans. Our results also highlight some important points
that need to be considered when translating preclinical
findings from dogs to humans.
First, it is worth mentioning that drug-induced QT
prolongation is very small in dogs, as expressed by shal-
low slope and wide credible intervals for the slope param-
eter. Whereas we have shown in previous investigations
that dogs may be less sensitive to QT-prolonging effects
(Chain and Dubois et al. 2013; Dubois et al. 2014, 2016a,
b), we believe that the lower exposure levels achieved in
dogs also played an important role in the precision of the
parameter estimates.
It is well established that not only the physiological
(baseline) QT values are very different between dogs and
humans, but also that sensitivity to the drug effect on the
QT interval varies between the two species. This is
reflected in the slope of the linear drug–concentration–ef-
fect relationship, where the slope of the curve reflects the
sensitivity to the drug in terms of the change in QT inter-
val (in ms) per unit of drug concentration (e.g., in nM).
In a previous investigation, analyzing the effects of 10 dif-
ferent drugs, it has been demonstrated that there is a
mean 11.6-fold difference in the slope of the concentra-
tion–effect relation between dogs and humans (Dubois
et al. 2016a,b). In this investigation this same factor was
used to predict the effect of methadone on the QT in
humans from the slope parameter estimate in dogs.
The 95% CI for QTc0 in this study was considerably
large. We have no clear explanation for the observed vari-
ability. An important observation in this respect is that
correction for heart rate does not result in an appreciable
reduction in the variability, as shown in Figure 2, where
the time courses of both QT and QTc are presented in
the lower left panel. In this study an individual correction
factor for RR was calculated by an individual exponent
(a) per subject/animal. The use of alternative methods for
the heart rate correction (i.e., fixed exponents as Frideri-
cia or Bazett) did not result in further reduction in the
variation. Despite the variation in the data, the model
was able to describe the concentration–effect relationship
with sufficient precision to obtain realistic parameter esti-
mates. In addition, given that our protocols were
performed in a blinded manner, experiments in dogs were
designed according to a typical safety pharmacology pro-
tocol, without correcting for the currently known inter-
species differences in drug metabolism. Such a mismatch
occurs despite current recommendations by ICH S7A,
which aim at plasma exposure levels that ‘include and
exceed the primary pharmacodynamic or therapeutic
range’ (International committee of Harmonisation 2000).
Interspecies differences in drug disposition
Differences or discrepancies in pharmacokinetic properties
are not a unique feature of methadone (Garrett et al.
1985). Therefore, attention to the dose rationale in exper-
imental protocols is crucial for accurate extrapolation,
translation, and interpretation of proarrhythmic or dro-
motropic effects in preclinical species. On the other hand,
the striking differences in the pharmacokinetics of metha-
done between dogs and humans make this case a very
interesting point for discussion from a drug development
perspective (Florian et al. 2012). We have thus far
endorsed the views that characterization of PKPD rela-
tionships in animals in conjunction with early PKPD data
in humans should provide sufficient evidence about the
probability of QT interval prolongation ≥10 ms in
humans, without relying on the need for a TQT study as
the final confirmatory step. Our findings seem to support
that view and raise a major concern about the role of
clinical pharmacology in safety evaluation. Despite having
a consolidated role in regulatory processes, the use of
quantitative pharmacology concepts in preclinical safety
research remains very limited. Of particular relevance is
the possibility of using PKPD relationships in conjunction
with allometric scaling principles to support dose selec-
tion in toxicology and safety pharmacology experiments
(Sahota et al. 2014).
Another interesting feature of this exercise with metha-
done are the differences in enantioselective metabolism
observed between species, which applies to a range of
compounds with chiralic properties or which yield
metabolites with affinity for hERG or other ion channels.
According to Eap et al. (2007) the (S)-enantiomer of
methadone has a significantly higher affinity for hERG
compared with (R)-methadone (see Fig. 2S in supplemen-
tal results). Interestingly, in humans CYP2B6 has been
found to be a major contributor to the elimination of
methadone, which primarily metabolizes (S)-methadone
(Chang et al 2011). By contrast, in dogs this CYP2B iso-
zyme is not available (Martignoni et al. 2006). In theory,
the presence of higher levels of (S)-methadone in humans
as compared to dogs, lower clearance, and a difference in
potency of the two moieties (2 vs. 7 lM for (S)- and
(R)-methadone) would be sufficient to explain differences
2017 | Vol. 5 | Iss. 1 | e00284
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in the QT prolonging effects between dogs and humans
(Florian et al. 2012). Unfortunately, in the current drug
screening paradigm barely any of the aforementioned
points are accounted for in a quantitative manner when
assessing the proarrhythmic risk of a candidate molecule
(Brocks 2006; Hutt 2007). In these circumstances, the use
of a model-based approach will not replace hard evidence
of experimental data, but can be used as a tool to explore
the impact of interspecies differences. Inferential methods
are available that would allow assessment of a range of
simulation scenarios based on previously observed class
effects or by simple sensitivity analysis.
Drug-specific parameters as the basis for
translating preclinical findings
The methadone example offers another important insight
into the requirements for translational research. The
Figure 3. Predicted probability of QT interval prolongation of ≥ 10 msec (upper panels) and ≥5 msec (lower panels) in humans based on a typical
FTIH study design. Scenarios include the average (first and third row) and worst case scenario (second and fourth row) for the slope parameter
values derived by the extrapolation from dogs. Given the gender differences in QT interval, predictions are stratified by gender: males are shown
in the right panels, whereas females are depicted in the left panels. Blue line indicates the mean probability estimate; redlines: 90% credible
intervals. The dashed lines indicate the observed Cmax range at the highest dose level (500 mg) used in the simulated study.
ª 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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predictive performance of a PKPD model or the predic-
tive value of experimental findings in humans cannot be
taken for granted without further understanding of the
processes underpinning drug disposition and mechanism
of action, that is, the underlying substrates. We have
demonstrated that a correlation can be established
between drug-specific parameters in dogs and humans. In
fact, the rationale for a correlation between the slope
parameter is supported by evidence showing that the
canine Ether-a-Go-Go (cERG) potassium channel plays
the same role in the action potential repolarization,
contributing to the drug-related QT prolongation with
selectivity and sensitivity somewhat comparable to the
channel in humans hERG (Haushalter et al. 2008). Such a
correlation has been defined under the assumption that
hERG inhibition by the parent compound explains the
observed changes in QT interval in both species. Conse-
quently, after correcting for differences in drug disposi-
tion, any discrepancies in the magnitude of the
proarrhythmic effect of a compound in dogs and humans
may be assigned to intrinsic differences in the biological
systems, for example, hERG and ion channel density.
Figure 4. Predicted probability of QT interval prolongation of ≥10 msec (upper panels) and ≥5 msec (lower panels) in humans based on a time-
matched baseline TQT study design. Scenarios include the average (first and third row) and worst case scenario (second and fourth row) for the
slope parameter values derived by the extrapolation from dogs. Given the gender differences in QT interval, predictions are stratified by gender:
males are shown in the right panels, whereas females are depicted in the left panels. Blue line indicates the mean probability estimate; redlines:
90% credible intervals. The dashed lines indicate the observed Cmax range at the highest dose level (500 mg) used in the simulated study.
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Our simulation scenarios do not predict the same effect
size described by Florian et al. (2012). In their work, a
10-ms increase was associated with Cmax values observed
after administration of a 200-mg dose of methadone. By
contrast, at this dose level the predicted effect in healthy
subjects was marginal; our results suggest a 50% probabil-
ity of ≥5 msec increase around the Cmax after a 500 mg
dose. Such a discrepancy does not necessarily represent
inaccuracies in the estimates of the drug-specific proper-
ties, but seem to reflect the differences in methadone dis-
position in humans (i.e., enantioselective metabolism) as
well as other clinical factors. In fact, we have previously
shown that considerable differences may exist between
drug-induced effects in controlled clinical trials and
observed QT prolongation in real-life conditions (Chain
et al. 2013). In addition, one should recognize that the
analysis of PKPD data based on a limited range of doses
may lead to overestimation of drug-specific parameters
(e.g., slope). This limitation can be seen in the work by
Roy et al. (2011), who have shown drug-induced-cor-
rected QT interval prolongation in patients receiving rela-
tively low daily doses of methadone therapy, with no
evidence of a dose–response relationship. Even though an
exercise involving the translation from animal to humans
to real-life conditions was out of the scope of our work,
the use of a worst case scenario for slope estimates
allowed us to describe effect sizes in line with those
reported by Florian et al. (2012) and Martell et al.
(2005). The observed effect was detectable only in the
context of a TQT study most likely due to the inclusion
of both therapeutic and supratherapeutic exposures of
methadone. A summary of the limitations of the current
approach and perspectives for improved cardiovascular
safety can be founded in the supplemental material S1.
Conclusions
The objective of our study was to demonstrate that QT
interval prolongation in humans can be predicted from
preclinical data in conscious dogs, by extrapolating the
slope of the linear concentration–effect relationship, which
differs from humans by a factor of 11.6 (Dubois et al.
2016a,b). In addition, our approach enables the characteri-
zation of different thresholds, as shown for prediction of a
probability of a 10-ms and 5-ms prolongation.
The results from this extensive set of simulations also
support the use of preclinical data from safety pharmacol-
ogy protocols in dogs to detect the prolongation of QT
interval in humans irrespective of the drug effect size.
Our findings illustrate how concentration–QT prolonga-
tion relationships can be extrapolated from dogs and
combined with data from FTIH studies, enabling the
characterization of the safety profile of a compound in
early clinical development. This approach is in alignment
with the activities suggested by the CSCR/IQ consortium,
which is aimed at establishing the feasibility of incorpo-
rating QT measurements to single and multiple ascending
doses (SAD/MAD) studies and to replace TQT studies
(Darpo et al. 2014). On the other hand, this exercise
made clear that differences in drug disposition as well as
selectivity of action needs to be considered for the accu-
rate translation of experimental findings from preclinical
species to humans. These factors need to be accounted
for, but are often overlooked during the progression of
candidate molecules into clinical development.
We recommend the adoption of the approach by R&D
as it may provide the opportunity to further validate the
correlation between drug-specific parameters in dogs and
humans. In addition, it has become evident that availabil-
ity of relevant data on drug disposition is essential for the
accurate estimation of the probability of QT prolongation
in humans.
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